Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CytoMed TherapeuticsGDTC -3.16%27 3-Year Book Growth Rate is 120.50% as of Dec. 2025, which is at its 10-year median of 120.50. GuruFocus rates GDTC with a GF Score™ of 27/100. The stock has 2 warning signs investors should review. Among 1,129 Biotechnology companies, CytoMed Therapeutics ranks better than 98.67% on this metric.
During the past 12 months, CytoMed Therapeutics's average Book Value per Share Growth Rate was -25.40% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 120.50% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 73.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 6 years, the highest 3-Year average Book Value per Share Growth Rate of CytoMed Therapeutics was 181.00% per year. The lowest was 48.90% per year. And the median was 120.50% per year.
CytoMed Therapeutics (NAS:GDTC) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
CytoMed Therapeutics 3-Year Book Growth Rate Related Terms
GDTC vs LNAI, AZTR, MTVA: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, CytoMed Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoMed Therapeutics 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytoMed Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where CytoMed Therapeutics's 3-Year Book Growth Rate falls into.
CytoMed Therapeutics 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 120.50% mean?
CytoMed Therapeutics (GDTC) has a 3-Year Book Growth Rate of 120.50% as of Dec. 2025. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for CytoMed Therapeutics and its competitors. This is near median its historical median of 120.50. Over the past decade, CytoMed Therapeutics' 3-Year Book Growth Rate has ranged from 48.90 to 181.00. According to the industry distribution chart, CytoMed Therapeutics ranks #15 out of 1129 companies in the Biotechnology industry, placing it in the top 1.3%.
Is CytoMed Therapeutics' 3-Year Book Growth Rate too high?
CytoMed Therapeutics' current 3-Year Book Growth Rate of 120.50% is near median its 10-year median of 120.50. Over the past 10 years, this metric has ranged from a low of 48.90 to a high of 181.00. Based on the distribution chart, CytoMed Therapeutics ranks #15 out of 1129 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CytoMed Therapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does CytoMed Therapeutics' 3-Year Book Growth Rate compare to LNAI and AZTR?
According to the Biotechnology industry distribution chart, CytoMed Therapeutics ranks #15 out of 1129 companies for 3-Year Book Growth Rate. This places CytoMed Therapeutics in the top 1% of its industry — outperforming the majority of peers. Historically, CytoMed Therapeutics' own 3-Year Book Growth Rate has ranged from 48.90 to 181.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for CytoMed Therapeutics and its competitors. CytoMed Therapeutics's current 3-Year Book Growth Rate is 120.50%, which is near median its own 10-year median of 120.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoMed Therapeutics stock overvalued right now?
CytoMed Therapeutics (GDTC) has a current 3-Year Book Growth Rate of 120.50%. The current 3-Year Book Growth Rate is 120.50%, which is near median its 10-year median of 120.50. CytoMed Therapeutics' overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For CytoMed Therapeutics (GDTC), the current 3-Year Book Growth Rate is 120.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
27GF Score
Get the complete analysis for GDTC
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GDTC has been successfully added to your 
